​

Capricor Therapeutics (CAPR) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChartTranscripts

CAPR Stock Forecast

Capricor Therapeutics (CAPR) stock forecast, based on 6 Wall Street analysts, predicts a 12-month average price target of $17.50, with a high of $17.50 and a low of $17.50. This represents a 81.54% increase from the last price of $9.64.

- $5 $10 $15 $20 $25 High: $17.5 Avg: $17.5 Low: $17.5 Last Closed Price: $9.64

CAPR Stock Rating

Capricor Therapeutics stock's rating consensus is Buy, based on 6 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 6 Buy (100.00%), 0 Hold (0.00%), 0 Sell (0.00%), and 0 Strong Sell (0.00%).

Buy
Total 6 0 6 Strong Sell Sell Hold Buy Strong Buy

CAPR Price Target Upside V Benchmarks

TypeNameUpside
StockCapricor Therapeutics81.54%
SectorHealthcare Stocks 33.91%
IndustryBiotech Stocks 83.49%

Price Target Trends

1M3M12M
# Anlaysts--6
Avg Price Target--$12.67
Last Closing Price$9.64$9.64$9.64
Upside/Downside--31.43%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Apr, 2534---7
Mar, 2534---7
Feb, 2534---7
Jan, 2534---7
Dec, 2434---7
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Oct 21, 2024Edward TenthoffPiper Sandler$17.50$9.4385.58%81.54%
Oct 14, 2024Leland GershallOppenheimer$21.50$8.89141.84%123.03%
Sep 25, 2024Jason McCarthyMaxim Group$12.50$4.55174.73%29.67%
Sep 25, 2024Joseph PantginisH.C. Wainwright$10.00$2.78259.71%3.73%
Sep 17, 2024Leland GershallOppenheimer$7.50$2.54195.28%-22.20%
May 16, 2024Leland GershallOppenheimer$7.00$2.82148.23%-27.39%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Oct 21, 2024Piper SandlerOverweightinitialise
Oct 14, 2024OppenheimerOutperformOutperformhold
Oct 11, 2024H.C. WainwrightBuyBuyhold
Sep 25, 2024Maxim GroupBuyBuyhold
Sep 24, 2024Cantor FitzgeraldOverweightOverweighthold
Sep 20, 2024OppenheimerBuyBuyhold
Sep 18, 2024H.C. WainwrightBuyBuyhold
Sep 17, 2024OppenheimerOutperformOutperformhold
Jul 02, 2024OppenheimerBuyBuyhold
Jul 02, 2024H.C. WainwrightBuyBuyhold

Financial Forecast

EPS Forecast

$-3 $-2 $-1 $0 $1 $2 $3 $4 $5 $6 Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-0.87$-0.84$-1.18$-0.83$-1.15----
Avg Forecast$-0.88$-0.80$-1.22$-1.04$-1.19$-0.98$0.41$1.25$3.48
High Forecast$-0.64$-0.58$-0.59$-0.87$-0.64$2.04$1.63$2.20$5.07
Low Forecast$-1.06$-0.96$-2.51$-1.21$-1.35$-1.90$-1.20$-0.94$2.07
Surprise %-1.14%5.00%-3.28%-20.19%-3.36%----

Revenue Forecast

$0 $80M $160M $240M $320M $400M Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$310.25K$244.90K$2.55M$25.18M$22.27M----
Avg Forecast$252.00K$222.50K$1.59M$21.05M$20.97M$44.47M$113.29M$184.74M$287.81M
High Forecast$291.47K$257.35K$2.89M$28.47M$21.45M$60.14M$113.29M$189.52M$389.25M
Low Forecast$198.26K$175.05K$960.35K$14.47M$20.66M$30.58M$113.29M$179.97M$197.92M
Surprise %23.12%10.07%59.84%19.62%6.21%----

Net Income Forecast

$-100M $-50M $0 $50M $100M $150M Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-13.48M$-19.41M$-29.02M$-22.29M$-40.47M----
Avg Forecast$-23.56M$-21.42M$-32.58M$-27.85M$-34.11M$-40.14M$18.31M$16.87M$93.10M
High Forecast$-17.03M$-15.48M$-15.73M$-23.31M$-17.12M$54.74M$43.65M$58.91M$135.75M
Low Forecast$-28.36M$-25.79M$-67.10M$-32.39M$-36.08M$-50.88M$-32.13M$-25.17M$55.30M
Surprise %-42.80%-9.40%-10.93%-19.97%18.63%----

CAPR Forecast FAQ

Is Capricor Therapeutics stock a buy?

Capricor Therapeutics stock has a consensus rating of Buy, based on 6 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 6 Buy, 0 Hold, 0 Sell, and 0 Strong Sell, reflecting a consensus that Capricor Therapeutics is a favorable investment for most analysts.

What is Capricor Therapeutics's price target?

Capricor Therapeutics's price target, set by 6 Wall Street analysts, averages $17.5 over the next 12 months. The price target range spans from $17.5 at the low end to $17.5 at the high end, suggesting a potential 81.54% change from the previous closing price of $9.64.

How does Capricor Therapeutics stock forecast compare to its benchmarks?

Capricor Therapeutics's stock forecast shows a 81.54% upside, outperforming the average forecast for the healthcare stocks sector (33.91%) and underperforming the biotech stocks industry (83.49%).

What is the breakdown of analyst ratings for Capricor Therapeutics over the past three months?

  • April 2025: 42.86% Strong Buy, 57.14% Buy, 0% Hold, 0% Sell, 0% Strong Sell.
  • March 2025: 42.86% Strong Buy, 57.14% Buy, 0% Hold, 0% Sell, 0% Strong Sell.
  • February 2025: 42.86% Strong Buy, 57.14% Buy, 0% Hold, 0% Sell, 0% Strong Sell.

What is Capricor Therapeutics’s EPS forecast?

Capricor Therapeutics's average annual EPS forecast for its fiscal year ending in December 2025 is $-0.98, marking a -14.78% decrease from the reported $-1.15 in 2024. Estimates for the following years are $0.41 in 2026, $1.25 in 2027, and $3.48 in 2028.

What is Capricor Therapeutics’s revenue forecast?

Capricor Therapeutics's average annual revenue forecast for its fiscal year ending in December 2025 is $44.47M, reflecting a 99.67% increase from the reported $22.27M in 2024. The forecast for 2026 is $113.29M, followed by $184.74M for 2027, and $287.81M for 2028.

What is Capricor Therapeutics’s net income forecast?

Capricor Therapeutics's net income forecast for the fiscal year ending in December 2025 stands at $-40.142M, representing a -0.80% decrease from the reported $-40.467M in 2024. Projections indicate $18.31M in 2026, $16.87M in 2027, and $93.1M in 2028.